Patents by Inventor Davide Ruggero

Davide Ruggero has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ELONGATION FACTOR 1-ALPHA INHIBITORS AND USES THEREOF
    Publication number: 20230135758
    Abstract: Disclosed herein, inter alia, are compounds for inhibiting Elongation Factor 1-alpha and uses thereof.
    Type: Application
    Filed: February 5, 2021
    Publication date: May 4, 2023
    Inventors: John Taunton, Davide Ruggero, Haoyuan Wang, Keely Oltion, Haojun Yang
  • Cancer Treatment Targeted to Tumor Adaptive Responses to Protein Synthesis Stress
    Publication number: 20220152035
    Abstract: In cancers such as prostate cancer, the combination of PTEN loss and activation of Myc activates an adaptive stress response that enables tumor cells to escape the stress of massively upregulated protein synthesis. This pro-survival response is mediated by the PERK-phosphorylated eIF2? axis of the UPR adaptive response. Agents that disrupt PERK-eIF2? pathways disrupt the adaptive response and lead to cancer cell death from uncontrolled growth. For example, ISRIB and derivatives may be employed as therapeutic agents to disrupt PERK-mediated adaptive mechanisms. Additionally PTEN loss and activation of Myc provides a diagnostic marker that enables better prognosis and the selection of amenable treatments.
    Type: Application
    Filed: January 14, 2022
    Publication date: May 19, 2022
    Applicant: The Regents of the University of California
    Inventors: Davide Ruggero, Hao Nguyen, Peter Carroll, Crystal Conn
  • Cancer treatment targeted to tumor adaptive responses to protein synthesis stress
    Patent number: 11253522
    Abstract: In cancers such as prostate cancer, the combination of PTEN loss and activation of Myc activates an adaptive stress response that enables tumor cells to escape the stress of massively upregulated protein synthesis. This pro-survival response is mediated by the PERK-phosphorylated eIF2? axis of the UPR adaptive response. Agents that disrupt PERK-eIF2? pathways disrupt the adaptive response and lead to cancer cell death from uncontrolled growth. For example, ISRIB and derivatives may be employed as therapeutic agents to disrupt PERK-mediated adaptive mechanisms. Additionally PTEN loss and activation of Myc provides a diagnostic marker that enables better prognosis and the selection of amenable treatments.
    Type: Grant
    Filed: April 28, 2019
    Date of Patent: February 22, 2022
    Assignee: The Regents of the University of California
    Inventors: Davide Ruggero, Hao Nguyen, Peter Carroll, Crystal Conn
  • Cancer Treatment Targeted to Tumor Adaptive Responses to Protein Synthesis Stress
    Publication number: 20190328740
    Abstract: In cancers such as prostate cancer, the combination of PTEN loss and activation of Myc activates an adaptive stress response that enables tumor cells to escape the stress of massively upregulated protein synthesis. This pro-survival response is mediated by the PERK-phosphorylated eIF2? axis of the UPR adaptive response. Agents that disrupt PERK-eIF2? pathways disrupt the adaptive response and lead to cancer cell death from uncontrolled growth. For example, ISRIB and derivatives may be employed as therapeutic agents to disrupt PERK-mediated adaptive mechanisms. Additionally PTEN loss and activation of Myc provides a diagnostic marker that enables better prognosis and the selection of amenable treatments.
    Type: Application
    Filed: April 28, 2019
    Publication date: October 31, 2019
    Inventors: Davide Ruggero, Nguyen Hao, Peter Carroll, Crystal Conn
  • USE OF TRANSLATIONAL PROFILING TO IDENTIFY TARGET MOLECULES FOR THERAPEUTIC TREATMENT
    Publication number: 20190136321
    Abstract: The present invention provides methods of identifying an agent or drug candidate molecule, validating a target, and identifying normalizing therapeutics that modulates translation, such as in an oncogenic signaling pathway, in a biological sample as determined by translational profiling of one or more genes in the biological sample. The present invention also provides diagnostic and therapeutic methods using the translational profiling methods described herein.
    Type: Application
    Filed: October 15, 2018
    Publication date: May 9, 2019
    Inventors: Davide Ruggero, Andrew Hsieh, Merritt Edlind, Kevan M. Shokat, James Appleman, Steve Worland
  • USE OF TRANSLATIONAL PROFILING TO IDENTIFY TARGET MOLECULES FOR THERAPEUTIC TREATMENT
    Publication number: 20190093170
    Abstract: The present invention provides methods of identifying an agent that modulates an oncogenic signaling pathway in a biological sample by generating a translational profile of gene translational levels in the biological sample. The present invention also provides diagnostic and therapeutic methods using the translational profiling methods described herein.
    Type: Application
    Filed: October 12, 2018
    Publication date: March 28, 2019
    Inventors: Davide RUGGERO, Andrew HSIEH, Merritt EDLIND
  • Phosphoribosyl pyrophosphate synthetase 2 (PRPS2) as a therapeutic target in cancer treatment
    Patent number: 9765337
    Abstract: The present invention provides methods of selectively killing a cell, comprising contacting the cell with an agent that inhibits phospho-ribosyl pyrophophosphate synthetase 2 (PRPS2). The present invention also provides methods of identifying a candidate agent that selectively kills neoplastic cells that are Myc-hyperactivated via inhibition of PRPS2.
    Type: Grant
    Filed: January 22, 2014
    Date of Patent: September 19, 2017
    Assignee: The Regents of the University of California
    Inventors: Davide Ruggero, John Thomas Cunningham
  • MTOR modulators and uses thereof
    Patent number: 9629843
    Abstract: The present invention provides methods and compositions for selective modulation of certain protein kinases, and especially mTor complexes. The methods and compositions are particularly useful in inhibiting mTor selectively for therapeutic applications.
    Type: Grant
    Filed: June 5, 2015
    Date of Patent: April 25, 2017
    Assignees: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, INTELLIKINE, INC.
    Inventors: Kevan M. Shokat, David Fruman, Pingda Ren, Troy Edward Wilson, Liansheng Li, Andrew Hsieh, Morris Feldman, Beth Apsel, Yi Liu, Christian Rommel, Katrina Chan, Davide Ruggero, David Pearce, Matthew Janes
  • MTOR MODULATORS AND USES THEREOF
    Publication number: 20160000789
    Abstract: The present invention provides methods and compositions for selective modulation of certain protein kinases, and especially mTor complexes. The methods and compositions are particularly useful in inhibiting mTor selectively for therapeutic applications.
    Type: Application
    Filed: June 5, 2015
    Publication date: January 7, 2016
    Inventors: Kevan M. Shokat, David Fruman, Pingda Ren, Troy Edward Wilson, Liansheng Li, Andrew Hsieh, Morris Feldman, Beth Apsel, Yi Liu, Christian Rommel, Katrina Chan, Davide Ruggero, David Pearce, Matthew Janes
  • PHOSPHORIBOSYL PYROPHOSPHATE SYNTHETASE 2 (PRPS2) AS A THERAPEUTIC TARGET IN CANCER TREATMENT
    Publication number: 20150337316
    Abstract: The present invention provides methods of selectively killing a cell, comprising contacting the cell with an agent that inhibits phospho-ribosyl pyrophophosphate synthetase 2 (PRPS2). The present invention also provides methods of identifying a candidate agent that selectively kills neoplastic cells that are Myc-hyperactivated via inhibition of PRPS2.
    Type: Application
    Filed: January 22, 2014
    Publication date: November 26, 2015
    Inventors: Davide Ruggero, John Thomas Cunningham
  • USE OF TRANSLATIONAL PROFILING TO IDENTIFY TARGET MOLECULES FOR THERAPEUTIC TREATMENT
    Publication number: 20140288097
    Abstract: The present invention provides methods of identifying an agent or drug candidate molecule, validating a target, and identifying normalizing therapeutics that modulates translation, such as in an oncogenic signaling pathway, in a biological sample as determined by translational profiling of one or more genes in the biological sample. The present invention also provides diagnostic and therapeutic methods using the translational profiling methods described herein.
    Type: Application
    Filed: February 7, 2014
    Publication date: September 25, 2014
    Applicant: The Regents of The University of California
    Inventors: Davide Ruggero, Andrew Hsieh, Merritt Edlind, Kevan M. Shokat, James Appleman, Steve Worland
  • USE OF TRANSLATIONAL PROFILING TO IDENTIFY TARGET MOLECULES FOR THERAPEUTIC TREATMENT
    Publication number: 20140243356
    Abstract: The present invention provides methods of identifying an agent that modulates an oncogenic signaling pathway in a biological sample by generating a translational profile of gene translational levels in the biological sample. The present invention also provides diagnostic and therapeutic methods using the translational profiling methods described herein.
    Type: Application
    Filed: February 7, 2014
    Publication date: August 28, 2014
    Applicant: The Regents of the University of California
    Inventors: Davide Ruggero, Andrew Hsieh, Merritt Edlind
  • MTOR Modulators and Uses Thereof
    Publication number: 20110224223
    Abstract: The present invention provides methods and compositions for selective modulation of certain protein kinases, and especially mTor complexes. The methods and compositions are particularly useful in inhibiting mTor selectively for therapeutic applications.
    Type: Application
    Filed: July 8, 2009
    Publication date: September 15, 2011
    Applicants: The Regents of the University of California, a California corporation, Intellikine, Inc.
    Inventors: Kevan M. Shokat, David Fruman, Pingda Ren, Troy Edward Wilson, Liansheng Li, Andrew Hsieh, Morris Feldman, Beth Apsel, Yi Liu, Christian Rommel, Katrina Chan, Davide Ruggero, David Pearce, Matthew Janes